In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor. (5th September 2019)
- Record Type:
- Journal Article
- Title:
- In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor. (5th September 2019)
- Main Title:
- In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor
- Authors:
- Colling, Meaghan E.
Friedman, Kenneth D.
Dzik, Walter H. - Abstract:
- Patients with von Willebrand disease (VWD) often require treatment with supplemental von Willebrand factor (VWF) prior to procedures or to treat bleeding. Commercial VWF concentrates and more recently recombinant human VWF (rVWF) have replaced cryoprecipitate as the mainstay of therapy. In comparison with cryoprecipitate, the VWF content and multimer distribution under current manufacturing processes of these commercial products has not been reported. We measured the factor VIII (FVIII:C), VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CB), VWF platelet-binding activity by GPIbM enzyme-linked immunosorbent assay (VWF:GPIbM), and percentage of high-molecular-weight (HMWM) VWF in 3 pools of group A and O cryoprecipitate, 3 vials of VWF concentrate (Humate-P), and 1 lot of rVWF (Vonvendi). We found that both group O and group A cryoprecipitate have significantly higher ratios of VWF:GPIbM activity and FVIII:C activity relative to VWF:Ag and have better preservation of HMWM than Humate-P. Although not compared statistically, rVWF appears to have more HMWM VWF and a higher ratio of VWF:GPIbM to VWF:Ag than Humate-P and cryoprecipitate. The estimated acquisition cost for our hospital for treating one major bleeding episode was more than 4-fold higher with Humate-P and 7- to 10-fold higher with rVWF than with cryoprecipitate.
- Is Part Of:
- Clinical and applied thrombosis/hemostasis. Volume 25(2019)
- Journal:
- Clinical and applied thrombosis/hemostasis
- Issue:
- Volume 25(2019)
- Issue Display:
- Volume 25, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 25
- Issue:
- 2019
- Issue Sort Value:
- 2019-0025-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-09-05
- Subjects:
- antihemophilic factor/VWF complex (human) -- cryoprecipitate -- high-molecular-weight von Willebrand multimers -- von Willebrand disease -- recombinant von Willebrand factor
Hemostasis -- Periodicals
Thrombosis -- Periodicals
616.13 - Journal URLs:
- http://cat.sagepub.com/ ↗
http://journals.sagepub.com/home/cat ↗
http://www.sagepublications.com/ ↗ - DOI:
- 10.1177/1076029619873976 ↗
- Languages:
- English
- ISSNs:
- 1076-0296
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12787.xml